A gastrointestinal targeted therapy could reduce overall viral burden, inhibit disease progression, accelerate viral clearance, and block significant transmission routes.
Pulmotect, Inc., a clinical-stage biotechnology company and non-traditional Medical CBRN Defense Consortium (MCDC) member, is joining the fight against COVID-19.
"With discovery research supported by Medical Technology Enterprise Consortium, and now clinical development supported by our remarkable collaboration with the Naval Medical Research Center, this biotech-government partnership is proud to advance this molecule into clinical development and closer to the patients and doctors that need a better medicine to end the pandemic."
The DoD recently awarded Sibel Health $2.4 million through an MTEC award to support the developed and deployment of its wearable, COVID-19 monitoring sensor.
The enormity of the coronavirus threat called for a rapid response, and the MCDC OTA was a key factor in supporting an accelerated solution to help expand COVID-19 testing.
"We believe that Inhalon's inhaled therapy offers many attractive benefits for patients and the healthcare system that are not available with intravenous or other systemically-dosed treatments," said William Howell, president, Medical Technology Enterprise Consortium.
Vivacelle Bio, Inc., a non-traditional small business and Medical Technology Enterprise Consortium (MTEC) member, was awarded $5.3 million to research treatment of septic shock.
The Medical CBRN Defense Consortium (MCDC) used the power of collaboration to drive innovation in response to the COVID-19 outbreak.
With funding from the Medical Technology Enterprise Consortium (MTEC), Centivax is developing an optimized antibody therapeutic to treat, as well as protect against, COVID-19.
Just weeks into the pandemic, the Medical Technology Enterprise Consortium (MTEC) reached out to its members and the public to seek ways to detect pre-symptomatic exposure to the virus through wearable diagnostic technology.
